FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Thomas David Hull III, the President and CEO of Kewaunee Scientific Corp (NASDAQ:KEQU), recently sold a portion of his holdings in the company. According to a recent SEC filing, Hull disposed of 1,844 shares of common stock on April 14, 2025. The transaction comes as InvestingPro data shows the company maintains a "GREAT" financial health score, despite the stock trading near its 52-week low of $30.82. The shares were sold at a weighted average price of $32.44, resulting in a total transaction value of approximately $59,819. Following this sale, Hull retains ownership of 36,072 shares in the company. The transaction was part of multiple trades, with prices ranging between $32.00 and $33.00 per share. Notably, while the stock trades at an attractive P/E ratio of 5.25, management has been actively buying back shares, suggesting confidence in the company’s value proposition. Subscribers to InvestingPro can access 8 additional key insights about KEQU’s performance and valuation metrics.
In other recent news, Kewaunee Scientific Corporation has announced an expansion of its share repurchase program, allowing for the repurchase of an additional 100,000 shares of its common stock. This decision follows the completion of Kewaunee’s acquisition of Nu Aire, Inc. on November 1, 2024, which added biological safety cabinets and other laboratory equipment to its offerings. The original repurchase program, initiated on September 1, 2023, still had 11,176 shares available for repurchase before the expansion. Kewaunee’s management plans to resume share repurchases, considering factors such as market conditions and business capital needs. The company emphasizes that the repurchase program may be adjusted or discontinued based on market and capital conditions. These developments align with Kewaunee’s capital allocation strategy, aiming to create shareholder value. The company’s management will determine the timing and volume of repurchases, and there is no obligation to acquire a specific number of shares.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.